A post-treatment blood test could inform future cancer therapy decisions
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...
pharmaphorum4d
Kelun-Biotech first to bag TROP2 approval in lung cancer
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
Mirage News7h
Blood Test Post-Treatment May Guide Cancer Therapy
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of ...
Checkpoint Therapeutics: Pivoting From Approval To Gutsy Next Shot On Goal
Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...
Targeted Oncology5d
Exploring Targeted Treatments and Their AEs in EGFR-Mutated NSCLC
During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.
Pharmabiz5d
China NMPA approves Kelun-Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication
Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...
Business Insider10d
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
the potential of BDTX-1535 to address the unmet medical need for newly diagnosed NSCLC patients with non-classical EGFR mutations and benefit patients with NSCLC across multiple lines of therapy, the ...
Precision Medicine Online12d
Focus on Primary Resistance May Improve KRAS Inhibitor Strategies in Colorectal, Pancreatic Cancer
The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.